Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort.
Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort.
复制标题
DOI：
10.1038/bjc.2012.39
复制
发表时间：
2012-03-13
影响因子：
8.8
通讯作者：
Stone, S.
中科院分区：
文献类型：
--
作者：
Cuzick, J.;Berney, D. M.;Fisher, G.;Mesher, D.;Moller, H.;Reid, J. E.;Perry, M.;Park, J.;Younus, A.;Gutin, A.;Foster, C. S.;Scardino, P.;Lanchbury, J. S.;Stone, S.
关键词：
前列腺癌的自然病程是高度可变的，很难预测。我们以前曾指出，在经尿道前列腺电切术诊断的保守治疗队列中，细胞周期进展（CCP）评分是一个可靠的预后预测因子。更大的需求是预测经穿刺活检诊断的患者的结果。从石蜡标本中提取总RNA。从31个基因的表达水平计算CCP评分。临床变量包括中心复查的Gleason评分、基线前列腺特异性抗原水平、年龄、临床分期和疾病程度。主要终点是前列腺癌死亡。在单变量分析中（n=349），CCP评分每增加一个单位，前列腺癌死亡的风险比（HR）为2.02（95% CI（1.62，2.53），P<10−9）。CCP评分仅与标准预后因素弱相关，在多变量分析中，CCP评分占主导地位（增加一个单位的HR =1.65，95% CI（1.31，2.09），P=3 × 10−5），Gleason评分（P=5 × 10−4）和前列腺特异性抗原（PSA）（P=0.017）提供了显著的额外贡献。对于保守治疗的患者，CCP评分是迄今为止描述的癌症死亡结局的最强独立预测因子，并且可能证明在管理临床局限性前列腺癌方面有价值。
The natural history of prostate cancer is highly variable and it is difficult to predict. We showed previously that a cell cycle progression (CCP) score was a robust predictor of outcome in a conservatively managed cohort diagnosed by transurethral resection of the prostate. A greater need is to predict outcome in patients diagnosed by needle biopsy. Total RNA was extracted from paraffin specimens. A CCP score was calculated from expression levels of 31 genes. Clinical variables consisted of centrally re-reviewed Gleason score, baseline prostate-specific antigen level, age, clinical stage, and extent of disease. The primary endpoint was death from prostate cancer. In univariate analysis (n=349), the hazard ratio (HR) for death from prostate cancer was 2.02 (95% CI (1.62, 2.53), P<10−9) for a one-unit increase in CCP score. The CCP score was only weakly correlated with standard prognostic factors and in a multivariate analysis, CCP score dominated (HR for one-unit increase=1.65, 95% CI (1.31, 2.09), P=3 × 10−5), with Gleason score (P=5 × 10−4) and prostate-specific antigen (PSA) (P=0.017) providing significant additional contributions. For conservatively managed patients, the CCP score is the strongest independent predictor of cancer death outcome yet described and may prove valuable in managing clinically localised prostate cancer.
登录
查看更多内容
影响因子：
254.7
作者：
Jemal, Ahmedin;Siegel, Rebecca;Thun, Michael J.
通讯作者：
Thun, Michael J.
影响因子：
6.4
作者：
BRESLOW, N;CHAN, CW;TULINIUS, H
通讯作者：
TULINIUS, H
影响因子：
23.4
作者：
Soos, G;Tsakiris, I;Dezso, B
通讯作者：
Dezso, B
接受保守治疗的局限性前列腺癌男性的长期结果。
影响因子：
8.8
作者：
Cuzick, J.;Fisher, G.;Kattan, M. W.;Berney, D.;Oliver, T.;Foster, C. S.;Moller, H.;Reuter, V.;Fearn, P.;Eastham, J.;Scardino, P.
通讯作者：
Scardino, P.
影响因子：
51.1
作者：
Cuzick, Jack;Swanson, Gregory P.;Fisher, Gabrielle;Brothman, Arthur R.;Berney, Daniel M.;Reid, Julia E.;Mesher, David;Speights, V. O.;Stankiewicz, Elzbieta;Foster, Christopher S.;Moller, Henrik;Scardino, Peter;Warren, Jorja D.;Park, Jimmy;Younus, Adib;Flake, Dart D., II;Wagner, Susanne;Gutin, Alexander;Lanchbury, Jerry S.;Stone, Steven
通讯作者：
Stone, Steven